

## **IMDRF Stakeholder Open Forum**

# **Regulatory Updates ANMAT- Argentina**

Yesica Anastasio, M.A.

**Coordinator of the International Relations Program, ANMAT**

**September 26, 2023**

# About ANMAT

ANMAT's **objective** is to control and monitor the activities, processes and technologies related to drug products, **medical devices**, foods, household sanitizing products and cosmetics; as well as to surveil their efficacy and the detection of adverse events resulting from the consumption and use of said products.



**Service attitude**



**Confidentiality and Integrity**



**Commitment and sense of belonging**



**Response capacity**



**Reliability and credibility**



**Transparency**

# About ANMAT

# 1

**National Regulatory Authority** with capacities and resources based on Regulatory Science.

# 2

**Regulatory framework adapted** to international regulatory convergence and coherence criteria.

# 3

**Active involvement in the international arena**, with participation in several WGs from different fields.

# 4

**Being a part of the convergence and harmonization processes** within the IMDRF framework.



# Essential Principles of Safety and Performance of Medical Devices and IVD Medical Devices.



Based on:

**IMDRF/GRRP WG/N47FINAL:2018** Essential Principles of Safety and Performance of Medical Devices and IVD Medical Devices

# Postmarket Surveillance



## Main objectives:

- Update the concepts of Post-Marketing Surveillance
- Establish new deadlines and notification criteria.
- Database available

**INDUSTRY**



## ARGOS (software)

anmat  
PM\_regulados v1.0.0.0

A.N.M.A.T. - Administración Nacional de Medicamentos, Alimentos y Tecnología Médica

Razón Social Mis Trámites Ayuda Salir

Seleccione el trámite

Trámite a realizar:  
 Evento adverso  
 Acción de campo

Modalidad:  
 Retiro de Mercado  
 Modificación de producto


Ingrese su email:

**ADVERTENCIA**  
El trámite en Estado Borrador se encuentra en confección y aún no es válido como expediente en curso hasta tanto no complete todos los requisitos y pase al estado Enviado.

Generar trámite Completar trámite cargado

ACES SA, 30708684305 PM\_regulados v1.0.0.0 12 nuevas notificaciones

# Good Technovigilance Practices



## Based on:

**IMDRF/AE WG/N43** – IMDRF terminologies for categorized Adverse Event Reporting (AER): terms, terminology structure and codes

**ISO/TR 20416:2020** – Post-market surveillance for manufacturers



Post – market  
surveillance


Guidance for  
industry

MDRF/MDCE  
WG/N65  
Post-Market Clinical  
Follow-Up Studies

Based on:

**WHO 2021** – Guidance for post-market surveillance and market surveillance of medical devices, including in vitro diagnostics

# Medical Device Clinical Evaluation



- 1. IMDRF MDCE WG/N55:19**  
CLINICAL EVIDENCE - KEY DEFINITIONS AND CONCEPTS
- 2. IMDRF MDCE WG/N56:19**  
CLINICAL EVALUATION
- 3. IMDRF MDCE WG/N57:19**  
CLINICAL INVESTIGATION

**Internal working group for the implementation of these documents**



# CHALLENGES

ANMAT intends to continue joining regulatory convergence and harmonization processes that represent IMDRF foundational objectives

- Update medical device classification rules.
- New document about IVD clinical evidence
- Actively participate in new IMDRF WG.
- **Member of the Management Committee**

# Thank you

Yesica Anastasio

**Emails:** [yesica.anastasio@anmat.gob.ar](mailto:yesica.anastasio@anmat.gob.ar)  
[relaciones.internacionales@anmat.gob.ar](mailto:relaciones.internacionales@anmat.gob.ar)

---

**Disclaimer**

This document was produced by the International Medical Device Regulators Forum. There are no restrictions on the reproduction or use of this document; however, incorporation of this document, in part or in whole, into another document, or its translation into languages other than English, does not convey or represent an endorsement of any kind by the International Medical Device Regulators Forum.

Copyright 2021 by the International Medical Device Regulators Forum.